Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuradiab + Bevacizumab in Recurrent GBM
NCT00906516Phase 2Unknown
- Sponsor
- Bradmer Pharmaceuticals Inc.
- Start
- May 2009
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iodine i 131 monoclonal antibody 81c6 in glioblastoma multiforme (GBM), sponsored by Bradmer Pharmaceuticals Inc.. Status: unknown.
02
Drugs
iodine i 131 monoclonal antibody 81c6
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00906516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906516.